Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Unicycive Therapeutics (UNCY)
NASDAQ:UNCY
RESEARCH TOOLSreports
Unicycive Therapeutics (UNCY) Stock Price & Analysis
155 Followers
UNCY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.47 - $1.82
Previous Close$1.04
Volume220.50K
Average Volume (3M)395.60K
Market Cap
$39.11M
Enterprise Value$40.03M
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$923.00K
Price to Earnings (P/E)-0.8
Beta-3.35
Next Earnings
Aug 12, 2024EPS Estimate
-$0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.26
Shares Outstanding37,606,630
10 Day Avg. Volume199,844
30 Day Avg. Volume395,600
Standard Deviation0.58
R-Squared0.06
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)-1.60
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit59.31
Enterprise Value/Ebitda-1.42
Forecast
1Y Price Target
$5.88Price Target Upside465.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Unicycive Therapeutics News
PremiumStock Analysis & Ideas
These 2 ‘Strong Buy’ Penny Stocks Could Rally to $9, Says Piper Sandler
Bulls Say, Bears Say
Bulls Say
Financial StabilityUnicycive is financially stable with sufficient funding into the second half of 2024, ensuring the company is well-positioned to complete its trials and pursue potential FDA approval.
Market OpportunityWith the recent approval of Ardelyx's Xphozah, there is heightened awareness of the value and pricing potential for new drugs in the phosphate binder market, signaling a promising opportunity for OLC.
Product DevelopmentUnicycive announced the enrollment of the first patient in the OLC tolerability study, a crucial step forward in the drug's development pipeline for treating hyperphosphatemia in CKD patients.
Bears Say
Commercialization DelaysThe need for a tolerability study has delayed the NDA filing and commercialization of OLC, impacting operating expenses and timelines.
Partnership And Funding RisksRisks include potential failure to secure regulatory approvals or commercialization partners for UNI-494.
Regulatory ChallengesUnicycive reported a FY2023 net loss to common shareholders of $31.4M.
---
Ownership Overview
16.60% Insiders
0.88% Mutual Funds
56.93% Other Institutional Investors
25.59% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
UNCY FAQ
What was Unicycive Therapeutics’s price range in the past 12 months?
Unicycive Therapeutics lowest stock price was $0.47 and its highest was $1.82 in the past 12 months.
What is Unicycive Therapeutics’s market cap?
Currently, no data Available
When is Unicycive Therapeutics’s upcoming earnings report date?
Unicycive Therapeutics’s upcoming earnings report date is Aug 12, 2024 which is in 84 days.
How were Unicycive Therapeutics’s earnings last quarter?
Unicycive Therapeutics released its earnings results on May 13, 2024. The company reported -$0.61 earnings per share for the quarter, missing the consensus estimate of -$0.148 by -$0.462.
Is Unicycive Therapeutics overvalued?
According to Wall Street analysts Unicycive Therapeutics’s price is currently Undervalued.
Does Unicycive Therapeutics pay dividends?
Unicycive Therapeutics does not currently pay dividends.
What is Unicycive Therapeutics’s EPS estimate?
Unicycive Therapeutics’s EPS estimate is -$0.17.
How many shares outstanding does Unicycive Therapeutics have?
Unicycive Therapeutics has 37,606,630 shares outstanding.
What happened to Unicycive Therapeutics’s price movement after its last earnings report?
Unicycive Therapeutics reported an EPS of -$0.61 in its last earnings report, missing expectations of -$0.148. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Unicycive Therapeutics?
Among the largest hedge funds holding Unicycive Therapeutics’s share is RA Capital Management. It holds Unicycive Therapeutics’s shares valued at 3M.
---
Unicycive Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.88 (465.38% Upside)
$5.88 (465.38% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 11.0%
Last 30 Days ▲ 137.2%
Last 30 Days ▲ 137.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-25.71%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
92.58%
Trailing 12-Months
Company Description
Unicycive Therapeutics
Unicycive Therapeutics Inc is a biotechnology company dedicated towards developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.
---
UNCY Stock 12 Month Forecast
Average Price Target
$5.88
▲(465.38% Upside)
Technical Analysis
Best Analysts Covering UNCY
1 Year
1 Year Success Rate
9/19 ratings generated profit
1 Year Average Return
+10.93%
reiterated a buy rating 6 days ago
Copying Ed Arce's trades and holding each position for 1 Year would result in 47.37% of your transactions generating a profit, with an average return of +10.93% per trade.
---